For Immediate Release
Chicago, IL – November 12, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corp. NVDA, Walmart Inc. WMT, AbbVie Inc. ABBV, Pioneer Bancorp, Inc. PBFS and Aspira Women's Health Inc. AWHL.
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for NVIDIA, Walmart and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., Walmart Inc., AbbVie Inc. as well as two micro-cap stocks, Pioneer Bancorp, Inc. and Aspira Women's Health Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> AI Trade Comes Back Post-CoreWeave Numbers
Today's Featured Research Reports
NVIDIA’s shares have underperformed the Zacks Semiconductor - General industry over the past year (-12.9% vs. -3.7%). Per the Zacks analyst, China's restrictions limit data center opportunities for the company, while customer concentration, rising investment needs, supply commitments and credit guarantees increase business risks. Intensifying competition adds uncertainty.
However, broad AI infrastructure demand, Blackwell Ultra adoption and the expanding Vera Rubin platform strengthen NVIDIA's growth prospects. Customer diversification, product leadership and expanding software opportunities support its outlook.
(You can read the full research report on NVIDIA here >>>)
Walmart’s shares have outperformed the Retail - Supermarkets industry over the past year (+21.4% vs. +20.4%). The Zacks analyst believes that the company benefits from its scale, value positioning and strong omnichannel model. Healthy traffic, e-commerce growth, expanding advertising and membership businesses, and international diversification support its growth prospects.
Yet, elevated operating costs, pharmacy-related sales pressure and heavy capital spending weigh on profitability. Price investments may constrain margins, while currency fluctuations add uncertainty.
(You can read the full research report on Walmart here >>>)
AbbVie’s shares have outperformed the Medical - Products industry over the last six months (+41.4% vs. +28.4%). The Zacks analyst believes the company has offset Humira's patent-related sales decline with strong growth from Skyrizi and Rinvoq. Its expanding neuroscience portfolio, robust pipeline, new indication approvals and strategic acquisitions support long-term growth prospects.
However, Humira's continuing erosion, slowing oncology sales and macroeconomic pressures on its Aesthetics business remain significant challenges.
(You can read the full research report on AbbVie here >>>)
Pioneer’s shares have outperformed the Zacks Banks - Northeast industry over the past year (+37.7% vs. +27.2%). The Zacks analyst believes that the company benefits from wider spreads, deposit and loan growth, specialty-finance expansion and diversified fee-based businesses. Generally stable asset quality and a solid capital position support growth initiatives.
Yet acquisition-related expenses, litigation risks, higher funding costs and rising charge-offs could pressure profitability. Capital-ratio compression may also limit financial flexibility.
(You can read the full research report on Pioneer here >>>)
Aspira’s shares have underperformed the Zacks Medical - Instruments industry over the past year (-66.6% vs. +24.5%). The Zacks analyst believes that the company faces liquidity constraints, financing dependence and weakness in its core business. Its investment case remains highly execution-dependent, with significant risks surrounding commercialization and pipeline development.
However, ENDOinform targets an underserved market, while clinical validation and the Cleveland Clinic partnership offer growth potential. An established distribution network could also support future product launches.
(You can read the full research report on Aspira here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Walmart Inc. (WMT): Free Stock Analysis Report
NVIDIA Corporation (NVDA): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Pioneer Bancorp, Inc. (PBFS): Free Stock Analysis Report
Aspira Women's Health Inc. (AWHL): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).